Vertex Pharmaceuticals: Barclays raises target price to $626 from $617
VRTX•Barclays raised its target price for Vertex Pharmaceuticals to $626 from $617.
Related News
Canada research roundup: Aurora Cannabis, Fortis, Toromont Industries
ACB•
Palantir Technologies target price raised to $273 from $265
PLTR•
Euro zone wage growth to rebound slightly next year, ECB says
SPY•
India's AM Green targets full offtake for giant green ammonia plant by mid-2027
UNP•
Eka Ventures sees AI adoption driving demand for new security infrastructure
XLK•